Leakage of Clinical Trial Data and Personal Information
First written in FY2016. 3 of 7 entries say "Restated". Latest entry: FY2023-Q1.
0 other companies' latest entry also says "Other".
- FY2023-Q1Continuing information security enhancement costsAnnual report
「In Japan, higher costs for strengthening information security and other expenses were absorbed through the results of operating activities in the previous fiscal year and control of personnel expenses, resulting in higher revenue and a substantial operating profit year on year.」
It is stated that costs for strengthening information security continued to increase after the unauthorised access incident in the previous fiscal year. - FY2022-Q3Recognition of costs related to responding to unauthorised accessAnnual report
「Information security measures expenses 99,053」
Following unauthorised access at the Japanese head office and European subsidiary, ¥99.053 million in costs for investigation, recovery, enhanced security and other measures was actually recognised. - FY2022-Q2MaterialisedAnnual report
「On 3 October 2021, we detected signs of unauthorised third-party access to the servers of our Japanese head office. While strengthening our response structure, including with an external specialist investigative firm, and investigating and responding to the incident, we newly detected unauthorised third-party access at our European subsidiary on 21 October 2021. We are investigating the incidents and taking recovery measures in Japan and Europe, but information may have been stolen from our Company and its consolidated subsidiaries.」
Unauthorised third-party access was actually detected at the Japanese head office and a European subsidiary. The presence and scope of any information theft remain under investigation, and it is stated that the amount of any impact on financial position, operating results and other matters cannot reasonably be calculated. - FY2020RestatedAnnual report
「If the CRO industry as a whole loses the confidence of pharmaceutical companies due to the leakage of personal information relating to clinical trials in which the CRO industry, including our Group, was involved, or if our Group loses the confidence of pharmaceutical companies due to the leakage of personal information relating to clinical trials in which our Group was involved, a decline in the number of clinical trials entrusted to the Group or the commencement of litigation could affect our Group's performance.」
The risks of a loss of confidence, litigation and a decline in entrusted work due to the leakage of personal information and confidential information, such as case report forms, continue. - FY2018RestatedAnnual report
「If the CRO industry as a whole loses the confidence of pharmaceutical companies due to the leakage of personal information relating to clinical trials in which the CRO industry, including our Group, was involved, or if our Group loses the confidence of pharmaceutical companies due to the leakage of personal information relating to clinical trials in which our Group was involved, a decline in the number of clinical trials entrusted to the Group or the commencement of litigation could affect our Group's performance.」
The risks of a loss of confidence, litigation and a decline in entrusted work due to the leakage of personal information and confidential information, such as case report forms, continue. - FY2017RestatedAnnual report
「If the CRO industry as a whole loses the confidence of pharmaceutical companies due to the leakage of personal information relating to clinical trials in which the CRO industry, including our Group, was involved, or if our Group loses the confidence of pharmaceutical companies due to the leakage of personal information relating to clinical trials in which our Group was involved, a decline in the number of clinical trials entrusted to the Group or the commencement of litigation could affect our Group's performance.」
The risks of a loss of confidence, litigation and a decline in entrusted work due to the leakage of personal information and confidential information, such as case report forms, continue to be disclosed. - FY2016First statedAnnual report
「If our Group loses the confidence of pharmaceutical companies as a result of the leakage of personal information relating to clinical trials in which our Group was involved, a decline in the number of clinical trials entrusted to the Group or the commencement of litigation could affect our Group's performance.」
The leakage of personal information and confidential information, such as case report forms, is identified as a risk that could lead to a loss of confidence, litigation and a decline in entrusted work.